EMJ Podcast: Insights For Healthcare Professionals

This podcast was developed and funded by LEO Pharma and is intended only for healthcare professionals. Please note that this podcast was developed in accordance with the betamethasone dipropionate, calcipotriol monohydrate SmPCs. Click here for the UK Enstilar (betamethasone diproprionate, calcipotriol monohydrate) SmPC. Enstilar is indicated for the topical treatment of psoriasis vulgaris in adults. Please be aware that the label within your country may differ due to local regulations, and you should always consult your own label for prescribing and safety information about Enstilar. Topics Covered: How topical vehicle design can influence drug delivery, efficacy, tolerability, and patient experience Key principles of penetration, permeation, and absorption, and how formulation characteristics can affect drug delivery How formulation approaches, including penetration enhancers and barrier-conscious design, can influence treatment outcomes in inflammatory skin disease Speaker:  Leon Kirick

How can clinical trials better answer the questions that matter to patients and clinicians? In the final episode, Nuru Noor explains the importance of the estimand framework, how to interpret apparently conflicting trial results, and what Bayesian re-analysis can add to the evidence. The discussion also considers how future trials could compare treatment strategies rather than individual drugs, and which developments are most likely to transform inflammatory bowel disease research and care over the next 5–10 years. Timestamps: 00:34 – The estimand framework  01:58 – Conflicting trial evidence and Bayesian re-analysis  04:45 – Comparing treatment strategies  06:11 – The future of IBD treatment 

Can biomarkers help clinicians move beyond trial and error in inflammatory bowel disease treatment? In Part 2, Nuru Noor explores why precision medicine has been difficult to translate into routine clinical practice, and how metabolomics, lipidomics, and genotype–phenotype associations could improve our understanding of individual patients. He also discusses the challenges of choosing between an expanding range of therapies and determining when combination treatment offers meaningful benefits. Timestamps: 00:36 – Translating research into clinical practice  03:12 – Multi-omics   04:15 – Increasing number of treatment options  06:13 – Combination therapy 

In this episode of Onc Now, Lennard Lee explores the latest advances in personalised cancer vaccines, emerging clinical evidence, and the potential of agentic AI scientists to accelerate cancer discovery, transform drug development and shape the future of oncology.  Timestamps 00:00 - Introduction   00:55 - Origin of interest in cancer vaccines  02:40 - Latest developments in cancer vaccines  04:30 - Who benefits from cancer vaccines?  09:45 - Expanding access to cancer vaccines  13:35 - AI and personalised vaccine development  20:55 - Oxford's AI cancer scientist initiative  24:25 - AI's impact beyond cancer vaccines  29:30 - Three wishes for cancer's future 

How is the treatment paradigm for inflammatory bowel disease changing? Nuru Noor joins host Saranya Ravindran to discuss the impact of the PROFILE trial on Crohn's disease management, the role of early treatment, and the importance of long-term outcomes. This episode explores treat-to-target strategies, balancing objective measures of inflammation with patients' experiences, and deciding when treatment escalation is appropriate. Timestamps: 00:38 - The PROFILE trial 04:15 – Importance of patient quality of life 05:40 – Heterogeneity in IBD 07:34 – Balancing treatment benefit, burden, and long-term risk

How much do we really understand about modern inflammatory bowel disease (IBD) care? In this quickfire episode, Nuru Noor answers key questions on personalised medicine, treatment success, emerging research, biomarkers, and the growing range of IBD therapies. Discover his perspectives on what the field still misunderstands and what needs to change to improve outcomes for patients.

This podcast has been funded by Castle Biosciences. Traditional staging remains the foundation of risk assessment in cutaneous melanoma and cutaneous squamous cell carcinoma (cSCC), but it does not always tell the full story. In T1b–T2a melanoma, the decision on sentinel lymph node biopsy (SLNB) is not always clear, and in cSCC, clinicopathologic risk factors are incomplete predictors of metastatic risk. In this episode, Mohs and dermatologic surgeon Brent Moody joins host Sue Saville to discuss how gene expression profile (GEP) testing may add tumor biology to the staging information dermatologists already rely on. Beginning with melanoma, Moody reviews prospective, multicenter data from the DECIDE study on the DecisionDx-Melanoma i31-SLNB result, and also explains how personalized risk of recurrence and distant metastasis can inform follow-up in SLN-negative patients. He then turns to high-risk cSCC, discussing how DecisionDx-SCC 40-GEP class results factor into decisions about adjuvant radiation therapy. Speaker: Brent Moody; Heritage Medical Associates, Nashville, Tennessee, USA

In this episode of Hema Now, we sit down with Toby Eyre, Consultant Haematologist at Oxford University Hospitals, UK, to explore the latest advances in lymphoma and chronic lymphocytic leukaemia, discuss unanswered questions in mantle cell lymphoma, and consider how emerging research is shaping the future of lymphoma care.    Timestamps 00:00 - Introduction  01:04 - Journey into haematology and lymphoma  04:34 - Working at Oxford University Hospitals  06:55 - Advances in lymphoma and CLL  11:00 - Unanswered questions in mantle cell lymphoma  16:22 - Impact of major haematology conferences

What will cardiovascular prevention look like 10 years from now? In this forward-looking episode, Kausik Ray discusses emerging technologies and therapies that could transform clinical practice, including AI, digital health tools, genomics, polygenic risk scoring, and RNA-based medicines.   Timestamps:  00:00 – 01:09: Intro  01:10 – 03:46: Population interventions  03:47 – 06:43: Data opportunities  06:43 – 08:51: Novel therapies  08:52 – 11:03: Future prevention

The global rise in obesity, Type 2 diabetes, and chronic kidney disease is driving an increasing burden of cardiovascular disease. Kausik Ray examines the growing intersection between metabolic and cardiovascular health, highlighting the importance of earlier intervention, comprehensive risk assessment, and integrated care.   Timestamps:  00:00 – 01:20: Intro  01:21 – 03:40: Cardiometabolic risk  03:41 – 06:20: Lifestyle interventions  06:21 – 10:19: Early intervention